Koninklijke Philips N.V. (PHG) Cash Flow Statement

The 2025Q1 quarter shows operating cash flow of negative $981.9M against net income of $76.0M, a ratio of -12.92, which appears to reflect large working capital outflows of $1.4B rather than operating weakness alone. Conversely, 2025Q4 shows operating cash flow of $1.4B against net income of $395.0M, a 3.52 ratio that appears to be driven by working capital release, suggesting that reported profits and cash timing are substantially decoupled. Investors should monitor whether conversion normalizes over the trailing four quarters, as the current pattern warrants further investigation into the drivers of these working capital reversals.

The trajectory is heavily influenced by working capital timing, as the 2025Q4 peak of $1.3B in free cash flow appears inconsistent with the more modest $468.8M recorded in 2026Q3 and the $116.9M in 2026Q1. The 2026Q3 margin of 10.7% may suggest a more sustainable run-rate, though it remains dependent on continued working capital normalization. Investors should treat the single-quarter peak with caution and focus on whether free cash flow can sustain positive margins once one-time working capital benefits fade.

Capital expenditures of $159.9M in 2026Q3 and $165.7M in 2026Q1 are broadly in line with depreciation and amortization of roughly $250M to $380M per quarter, which may indicate that the installed asset base is being maintained rather than materially expanded. The distinction between maintenance and growth capex is not separately disclosed in the supplied data, so the degree to which spending supports new product vitality cannot be verified. Investors should monitor whether capex remains below depreciation over time, as sustained underinvestment could weigh on the competitive position in imaging and therapy platforms.

The magnitude of these swings relative to net income suggests that reported profitability is poorly predictive of quarterly cash generation, which may reflect inventory build-up tied to large equipment orders or timing of receivable collections from hospital customers. The data does not disclose receivables, inventory, or payables separately, so the specific source of the reversals cannot be confirmed from the supplied figures. This warrants further investigation into the cash conversion cycle, particularly whether the 2026Q2 outflow of $308.0M reflects a sustained pattern or a temporary timing effect.

Summing the supplied quarters, operating cash flow is heavily depressed by the 2025Q1 outflow and the 2024Q2 weakness of $89.0M against net income of $451.0M, which may indicate that accrual-based earnings have overstated underlying cash generation during the period. The 2024Q4 and 2024Q3 periods show missing cash flow data, so a complete cumulative comparison cannot be verified and conclusions should be treated as indicative only. Investors should monitor whether a durable convergence between net income and operating cash flow emerges over the next several reporting periods.